Gout

Annals of Internal Medicine

Volumn 152, Issue 3, 2010, Pages

  Wilson, Jennifer F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BETAMETHASONE ACETATE; COLCHICINE; CYANOCOBALAMIN; FEBUXOSTAT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; LEVODOPA; METHOTREXATE; METHYLPREDNISOLONE ACETATE; MORPHINE; NAPROXEN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PETHIDINE; PREDNISOLONE; PROBENECID; PROTON PUMP INHIBITOR; RASBURICASE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THIAZIDE DIURETIC AGENT; TRIAMCINOLONE HEXACETONIDE; UNINDEXED DRUG; URATE; URIC ACID;

ALCOHOL CONSUMPTION; ALOPECIA; BACTERIAL ARTHRITIS; BLOOD PRESSURE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CARDIOVASCULAR RISK; CELLULITIS; CLINICAL TRIAL; DERMATITIS; DIABETES MELLITUS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; ECHOGRAPHY; EOSINOPHILIA; FIBER; FLUID RETENTION; FOOD INTAKE; GASTROINTESTINAL HEMORRHAGE; GENDER; GENETIC RISK; GLUCOSE BLOOD LEVEL; GLYCOGEN STORAGE DISEASE TYPE 1; GOUT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; INTERSTITIAL NEPHRITIS; JOINT ASPIRATION; JOINT RADIOGRAPHY; KIDNEY FAILURE; LEUKOCYTOSIS; LIFESTYLE MODIFICATION; LIVER FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC SYNDROME X; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; OBESITY; ORGAN TRANSPLANTATION; OSTEOARTHRITIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PURPURA; REACTIVE ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SARCOIDOSIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; THROMBOCYTE DYSFUNCTION; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; URTICARIA; VOMITING; WOUND HEALING;

EID: 75749109822     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-152-3-201002020-01002     Document Type: Review

References (52)

1. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582-7. [PMID: 15290739]
2. Wu EQ, Patel PA, Mody RR, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol. 2009;36:1032-40. [PMID: 19369467]
3. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421-6. [PMID: 3826098]
4. Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 2008;40:437-42. [PMID: 18327257]
5. Choi HK, Atkinson K, Karlson EW, et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165:742-8. [PMID: 15824292]
6. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093-103. [PMID: 15014182]
7. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336:309-12. [PMID: 18244959]
8. Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2004;51:1023-9. [PMID: 15593346]
9. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363:1277-81. [PMID: 15094272]
10. Lin JL, Tan DT, Ho HH, et al. Environmental lead exposure and urate excretion in the general population. Am J Med. 2002;113:563-8. [PMID: 12459402]
11. Suppiah R, Dissanayake A, Dalbeth N. High prevalence of gout in patients with Type 2 diabetes: male sex, renal impairment, and diuretic use are major risk factors. N Z Med J. 2008;121:43-50. [PMID: 18841184]
12. Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116:546-54. [PMID: 15063817]
13. Giordano N, Santacroce C, Mattii G, et al. Hyperuricemia and gout in thyroid endocrine disorders. Clin Exp Rheumatol. 2001;19:661-5. [PMID: 11791637]
14. Dehghan A, Köttgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372:1953-61. [PMID: 18834626]
15. Chen SY, Chen CL, Shen ML, et al. Clinical features of familial gout and effects of probable genetic association between gout and its related disorders. Metabolism. 2001;50:1203-7. [PMID: 11586494]
16. Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidencebased review. J Clin Oncol. 2008;26:2767-78. [PMID: 18509186]
17. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer. 2003;98:1048-54. [PMID: 12942574]
18. Coutinho Tde A, Turner ST, Peyser PA, et al. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens. 2007;20:83-9. [PMID: 17198917]
19. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25:39-42. [PMID: 15660333]
20. Fröhlich M, Imhof A, Berg G, et al. Association between Creactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23:1835-9. [PMID: 11128362]
21. Cao JJ, Arnold AM, Manolio TA, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation. 2007;116:32-8. [PMID: 17576871]
22. Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54:2688-96. [PMID: 16871533]
23. Choi HK. Diet, alcohol, and gout: how do we advise patients given recent developments? Curr Rheumatol Rep. 2005;7:220-6. [PMID: 15918999]
24. Niskanen LK, Laaksonen DE, Nyyssönen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546-51. [PMID: 15277287]
25. Malik A, Schumacher HR, Dinnella JE, et al. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15:22-4. [PMID: 19125136]
26. Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med. 2008;75 Suppl 5:S5-8. [PMID: 18822469]
27. Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol. 2009;36:1287-9. [PMID: 19369457]
28. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895-900. [PMID: 856219]
29. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician. 1999;59:925-34. [PMID: 10068714]
30. Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am. 1988;14:441-57. [PMID: 3051159]
31. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002:CD002296. [PMID: 12519573]
32. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009;38:411-9. [PMID: 18973929]
33. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987;17:301-4. [PMID: 3314832]
34. Baker JF, Schumacher HR. Update on gout and hyperuricemia. Int J Clin Pract. 2009. [PMID: 19909378]
35. Terkeltaub R, Furst DE, Bennett K, et al. Colchicine efficacy assessed by time to 50% reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the AGREE trial (poster). American College of Rheumatology Annual Scientific Meeting; 19 October 2009; Philadelphia. Accessed at http:// acr.confex.com/acr/ 2009/webprogram/ Paper15030.html on 18 December 2009.
36. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a doubleblind, randomised equivalence trial. Lancet. 2008;371:1854-60. [PMID: 18514729]
37. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312-24. [PMID: 16707532]
38. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356-60. [PMID: 12209479]
39. Perez-Ruiz F, Atxotegi J, Hernando I, et al. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term uratelowering therapy: a prospective study. Arthritis Rheum. 2006;55:786-90. [PMID: 17013833]
40. Avram Z, Krishnan E. Hyperuricaemia-where nephrology meets rheumatology. Rheumatology (Oxford). 2008;47:960-4. [PMID: 18443007]
41. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11:135-40. [PMID: 19296886]
42. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56. [PMID: 6691361]
43. Braden GL, Warzynski MJ, Golightly M, et al. Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol. 1994;70:145-51. [PMID: 8299230]
44. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-61. [PMID: 16339094]
45. Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48:188-94. [PMID: 19141576]
46. Edwards NL. Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford). 2009;48 Suppl 2:ii15-ii19. [PMID: 19447778]
47. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429-32. [PMID: 15570646]
48. Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol. 2007;13:266-8. [PMID: 17921794]
49. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9:R28. [PMID: 17352828]
50. Wolfe F, Cathey MA. The misdiagnosis of gout and hyperuricemia. J Rheumatol. 1991;18:1232-4. [PMID: 1941830]
51. Roddy E, Mallen CD, Hider SL, et al. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford). 2010;49:105-11. [PMID: 19920095]
52. Barber C, Thompson K, Hanly JG. Impact of a rheumatology consultation service on the diagnostic accuracy and management of gout in hospitalized patients. J Rheumatol. 2009;36:1699-704. [PMID: 19567626]